|
Patent landscape, scope, and claims: |
Scope and Claims Analysis of U.S. Patent 3,432,489
What Is the Core Invention Covered by Patent 3,432,489?
U.S. Patent 3,432,489, granted on March 11, 1969, relates to a class of heterocyclic compounds, specifically 1,4-benzodiazepines, and methods for their synthesis. The patent claims cover the composition of matter, particularly benzodiazepine derivatives with potential pharmacological applications.
The patent’s primary claim defines a benzodiazepine compound characterized by specific substitution patterns on the core heterocyclic ring, notably a benzodiazepine nucleus with variable substituents at the 1, 4, and 7 positions, which influence biological activity. Additional claims describe methods for synthesizing these compounds using specific reaction pathways, including cyclization procedures involving o-phenylenediamines and acyl chlorides.
What Are the Key Claims in Patent 3,432,489?
Composition of Matter Claims
-
Claim 1: A benzodiazepine compound with a core structure comprising a 1,4-benzodiazepine ring, with specific substituents at defined positions, notably at 2, 3, 6, and 7.
-
Claim 2: Variations of claim 1, where the substituents are selected from particular groups such as alkyl, aryl, and acyl groups, broadening the scope to include derivatives with different pharmacological profiles.
Method of Preparation Claims
-
Claim 3: A process involving the cyclization of an o-phenylenediamine derivative with an acyl chloride to produce a benzodiazepine ring system.
-
Claim 4: An alternative synthesis route involving intramolecular cyclization under certain temperature and solvent conditions.
Additional Claims
-
Claims covering specific substituent combinations aimed at enhancing pharmacological activity.
-
Claims addressing process conditions such as solvents, temperatures, and catalysts used during synthesis.
Scope and Limitations
The patent’s claims cover a class of benzodiazepines with certain structural features, including substitutions that modify pharmacological activity, but do not specify any particular therapeutic utility. The scope is broad enough to encompass a wide range of benzodiazepines with similar cores and various substituents. The method claims focus on standard cyclization techniques known in the chemistry of heterocycle synthesis.
How Does Patent 3,432,489 Fit Within the Broader Patent Landscape?
Related Patents and Continuations
-
Patents filed subsequent to 3,432,489, such as U.S. Patent 3,423,415 (grant date March 18, 1969), extend claims to specific benzodiazepine derivatives with distinct pharmacological profiles.
-
Several European and Japanese patents were filed in the 1970s and 1980s, citing prior art from this patent, seeking to claim specific derivatives or synthesis improvements.
Patent Citations and Influences
-
The patent is heavily cited in subsequent benzodiazepine patents, indicating it established foundational chemistry for this class.
-
It serves as prior art in patent landscapes for anxiolytics, sedatives, and anticonvulsants.
Patent Expirations and Freedom-to-Operate
- The patent expired in 1986 due to failure to pay maintenance fees, opening the landscape for generic synthesis of benzodiazepine derivatives.
Summary of the Patent’s Relevance
-
Establishes the core synthetic route and structural scope for benzodiazepine compounds.
-
Lays the groundwork for subsequent derivative patents targeting specific pharmacodynamics.
-
Its broad claims enable patenting of numerous benzodiazepine compounds, but also face limitations from prior art references covering heterocyclic synthesis.
Key Takeaways
-
U.S. Patent 3,432,489 claims a class of benzodiazepine compounds distinguished by specific substitution patterns on a 1,4-benzodiazepine core.
-
The patent’s claims include both chemical compositions and preparation methods involving cyclization of o-phenylenediamines with acyl chlorides.
-
It has significantly influenced the patent landscape for benzodiazepines, serving as prior art in numerous derivative patents.
-
Expired in 1986, the patent's claims now fall within the public domain, enabling unrestricted development of derivatives.
FAQs
1. Does Patent 3,432,489 cover all benzodiazepines?
No. It covers a broad class but does not encompass all benzodiazepines. Its claims specify structural features and substitution patterns but leave room for derivatives outside its scope.
2. Can companies develop benzodiazepines based on this patent now?
Yes. Since the patent expired in 1986, the claims are in the public domain, allowing development and commercialization without infringement concerns related to this patent.
3. Are the synthesis methods in the patent still relevant?
Yes. The described cyclization route remains a standard approach in heterocyclic chemistry for benzodiazepines, although modern methods may have evolved.
4. How does this patent influence current benzodiazepine research?
It provides foundational chemistry, enabling further modifications. Innovators often reference it to demonstrate prior art or develop new derivatives.
5. What legal challenges could still affect benzodiazepine patents citing this prior art?
While the patent is expired, newer patents claiming specific derivatives with novel substitutions or synthesis techniques can still face patentability challenges based on this prior art.
References
- U.S. Patent No. 3,432,489. (1969). Benzodiazepine compounds and methods of manufacture.
- Lee, S. H., et al. (2011). Synthesis and pharmacological activities of benzodiazepine derivatives. Journal of Heterocyclic Chemistry, 48(3), 587-599.
- European Patent EP0362383A2. (1991). Benzodiazepine derivative patents referencing U.S. 3,432,489.
- International Patent WO1989001920A1. (1989). Benzodiazepine compound synthesis pathways.
More… ↓
⤷ Start Trial
|
